Business Context and Reporting Period
This Form 8-K Current Report from Aptevo Therapeutics Inc. (APVO) covers events reported on January 30, 2026, and a subsequent announcement on February 3, 2026. The filing details a planned leadership transition effective April 1, 2026, involving the retirement of the current CEO and the appointment of a new CEO and Executive Chair.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and governance changes.
- New CEO Base Salary: $650,000 annually (Jeff Lamothe).
- New CEO Bonus Target: 60% of base salary.
- New CEO One-Time Award: $150,000 cash payable on the transition date.
- Executive Chair Base Salary: $275,000 annually (Marvin L. White).
- Executive Chair Bonus: Not eligible.
Material Changes Versus Prior Period
The primary material change is the restructuring of the company's top executive roles and Board composition effective April 1, 2026:
- CEO Transition: Marvin L. White is retiring as President and CEO; Jeff Lamothe (current COO) is assuming the role.
- Board Expansion: The Board size will increase from six to seven directors with Mr. Lamothe's appointment as a Class III director.
- Leadership Roles: Mr. White will transition to Executive Chair; John E. Niederhuber, M.D., will serve as Lead Independent Director.
- Severance Plan Modification: The Senior Management Severance Plan was amended to align Executive Chair benefits with CEO-level benefits and to delete Executive Vice President level benefits.
Guidance, Outlook, and Risks
The filing contains no financial guidance, revenue outlook, or discussion of market risks. Management commentary indicates the transition is intended to provide mentorship, continuity, and support for long-term growth. The resignation of Mr. White is explicitly stated as not being due to any disagreement with management or the Board regarding operations, policies, or practices.
Investor Verification Checklist
- Verify the exact effective date of the leadership transition (April 1, 2026).
- Confirm the total cash compensation impact of the one-time $150,000 award to the new CEO.
- Review the attached Press Release (Exhibit 99.1) for additional strategic context not included in the 8-K text.
- Monitor future filings for the formal appointment of the new CEO and any changes to the Board's committee assignments.